Messenger interference RNA therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 for mixed hyperlipidemia: the future of plozasiran and zodasiran
Expert Review of Clinical Pharmacology · 2024
DOI: 10.1080/17512433.2024.2423724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Zonghao Pan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Conemaugh Health System, Johnstown, PA, USA. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, Apolipoprotein C-III, Angiopoietin-like Proteins, Hyperlipidemias. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Mixed hyperlipidemia represents a substantial public health issue and a considerable burden on healthcare systems. Although the introduction of statins and LDL-cholesterol lowering agents have significantly reduced the incidence of atherosclerotic cardiovascular diseases (ASCVD), a significant portion of the population continues to exhibit ASCVD progression due to elevated triglyceride-rich lipoprotein (TRL) levels. This persistent risk has catalyzed the development of novel pharmacological interventions targeting these lipoproteins. AREAS COVERED: Our special report commenced with a targeted PubMed search using keywords such as 'plozasiran,' 'zodasiran,' and terms related to APOC3 and ANGPTL3. As the review progressed, emergent research questions guided further searches, allowing for the inclusion of additional relevant articles to comprehensively illustrate the linkage between TRLs and cardiovascular disease, discuss the roles of APOC3, ANGPTL3, and the pharmaceutical agents that target these proteins, and provide a comparison on the ARCHES-2 and MUIR trials. EXPERT OPINION: The ARCHES-2 and MUIR trials demonstrated effective triglyceride reduction by these therapies, yet it is uncertain if this correlates with significant clinical benefits. Advances in antisense oligonucleotide technology, especially the GalNAc delivery platform, show promise for personalized lipid management, though challenges such as cost and safety concerns remain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Conemaugh Health System, Johnstown, PA, USA.
- Department of Cardiology, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
- Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC, USA.
ORCID-Profile: Zonghao Pan, Muhammad Adnan Zaman
Zitieren
APA
Pan, Z., Zaman, M. A., Kalsoom, S., & Zhang, Y. (2024). Messenger interference RNA therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 for mixed hyperlipidemia: the future of plozasiran and zodasiran. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2423724
Vancouver
Pan Z, Zaman MA, Kalsoom S, Zhang Y. Messenger interference RNA therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 for mixed hyperlipidemia: the future of plozasiran and zodasiran. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2423724
BibTeX
@article{Pan2024,
author = {Pan, Zonghao and Zaman, Muhammad Adnan and Kalsoom, Sidra and Zhang, Yani},
title = {Messenger interference RNA therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 for mixed hyperlipidemia: the future of plozasiran and zodasiran},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
doi = {10.1080/17512433.2024.2423724}
}
EUVIMED